Novartis has a long way to go to make its twice-yearly cholesterol-lowering drug Leqvio the multi-billion-dollar blockbuster it is predicting – but took another step along that road today.

Evolucumab (Repatha) and alirocumab (Praluent) are injectable monoclonal antibodies. They have been joined by inclisiran ...

Q. Allergan ran a long-term study on silicone breast implants in 2009. I always wanted a more feminine body like the girls in the magazines, so I joined and got implants. They never followed up with ...

Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...

AstraZeneca has taken the decision not to move a PCSK9-targeting antisense drug licensed from Ionis into a phase 3 programme, removing a competitor to Novartis' rival therapy Leqvio. Like Leqvio ...

These drugs reduce the cholesterol your body makes ... alirocumab (Praluent), evolocumab (Repatha), and inclisiran (Leqvio)-- are injections that keep LDL receptors free to bind to LDL cholesterol ...

ALNY reports better-than-expected fourth-quarter results as both earnings and revenues beat estimates driven by higher ...